By comparing to L‐FABP and combining previous and present findings,[10, 11, 12, 13, 35] the pathogenic role of A‐FABP in the whole spectrum of liver disease from NAFLD to hepatocellular carcinoma is more straightforward, which further highlights the specificity and potential of A‐FABP as the therapeutic target in liver diseases among the lipid‐binding proteins. The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatotic liver disease.